CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
PerkinElmer and Verinata Health announced a strategic agreement for expanding access to Verinata’s Verifi test, a comprehensive noninvasive prenatal test (NIPT) for high-risk pregnancies. The Verifi test, performed at Verinata’s CLIA-certified California laboratory, uses a single maternal blood draw at as early as 10 weeks of pregnancy to detect multiple fetal chromosomal aneuploidies. Under terms of the collaboration, PerkinElmer will serve as an exclusive Verinata partner in joint sales and marketing of the Verifi test.
Read More »